Loading...

AC Immune

DB:IMR
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
IMR
DB
$319M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
  • AC Immune has significant price volatility in the past 3 months.
IMR Share Price and Events
7 Day Returns
-4.7%
DB:IMR
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-51.5%
DB:IMR
-10.6%
DE Biotechs
-6.2%
DE Market
IMR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AC Immune (IMR) -4.7% 2% -57.9% -51.5% - -
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • IMR underperformed the Biotechs industry which returned -10.6% over the past year.
  • IMR underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
IMR
Industry
5yr Volatility vs Market

IMR Value

 Is AC Immune undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for AC Immune. This is due to cash flow or dividend data being unavailable. The share price is €4.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AC Immune's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AC Immune's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:IMR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in CHF CHF-0.82
NasdaqGM:ACIU Share Price ** NasdaqGM (2019-04-18) in USD $4.72
NasdaqGM:ACIU Share Price converted to CHF reporting currency Exchange rate (USD/ CHF) 1.014 CHF4.79
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AC Immune.

DB:IMR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:ACIU Share Price ÷ EPS (both in CHF)

= 4.79 ÷ -0.82

-5.81x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AC Immune is loss making, we can't compare its value to the Europe Biotechs industry average.
  • AC Immune is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does AC Immune's expected growth come at a high price?
Raw Data
DB:IMR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.81x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-22.4%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AC Immune, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AC Immune's assets?
Raw Data
DB:IMR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in CHF CHF2.63
NasdaqGM:ACIU Share Price * NasdaqGM (2019-04-18) in USD $4.72
NasdaqGM:ACIU Share Price converted to CHF reporting currency Exchange rate (USD/ CHF) 1.014 CHF4.79
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:IMR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:ACIU Share Price ÷ Book Value per Share (both in CHF)

= 4.79 ÷ 2.63

1.82x

* Primary Listing of AC Immune.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AC Immune is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess AC Immune's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. AC Immune has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

IMR Future Performance

 How is AC Immune expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-22.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AC Immune expected to grow at an attractive rate?
  • AC Immune's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 0.2%.
Growth vs Market Checks
  • AC Immune's earnings are expected to decrease over the next 1-3 years, this is below the Germany market average.
  • AC Immune's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:IMR Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:IMR Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -22.4%
DB:IMR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 21.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:IMR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in CHF Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:IMR Future Estimates Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 26 671 -58 1
2022-12-31 341 261 -72 1
2021-12-31 0 10 -77 1
2020-12-31 0 -16 -71 1
2019-12-31 143 70 70 2
DB:IMR Past Financials Data
Date (Data in CHF Millions) Revenue Cash Flow Net Income *
2018-12-31 7 -44 -51
2018-09-30 22 -26 -32
2018-06-30 21 -22 -27
2018-03-31 20 -24 -29
2017-12-31 20 -22 -26
2017-09-30 5 -35 -35
2017-06-30 6 -19 -36
2017-03-31 25 -10 -10
2016-12-31 23 -6 -7
2016-09-30 22 -4 -8
2016-06-30 45 21 21
2016-03-31 39 16 17

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AC Immune's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • AC Immune's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:IMR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from AC Immune Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IMR Future Estimates Data
Date (Data in CHF Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -0.70 -0.70 -0.70 1.00
2022-12-31 -0.91 -0.91 -0.91 1.00
2021-12-31 -1.07 -0.86 -1.28 2.00
2020-12-31 -1.01 -0.85 -1.17 2.00
2019-12-31 1.06 1.12 1.00 2.00
DB:IMR Past Financials Data
Date (Data in CHF Millions) EPS *
2018-12-31 -0.82
2018-09-30 -0.54
2018-06-30 -0.48
2018-03-31 -0.50
2017-12-31 -0.46
2017-09-30 -0.62
2017-06-30 -0.65
2017-03-31 -0.20
2016-12-31 -0.14
2016-09-30 -0.17
2016-06-30 0.47
2016-03-31 0.38

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AC Immune will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess AC Immune's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AC Immune has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

IMR Past Performance

  How has AC Immune performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AC Immune's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AC Immune does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare AC Immune's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AC Immune's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
AC Immune's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AC Immune Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:IMR Past Revenue, Cash Flow and Net Income Data
Date (Data in CHF Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 7.19 -50.95 12.47
2018-09-30 22.21 -32.11 11.78
2018-06-30 20.98 -27.38 11.37
2018-03-31 19.71 -28.57 10.46
2017-12-31 20.26 -26.41 10.13
2017-09-30 5.26 -35.34 10.49
2017-06-30 5.52 -35.65 9.68
2017-03-31 24.73 -10.38 9.38
2016-12-31 23.21 -7.10 7.90
2016-09-30 22.10 -7.91 5.38
2016-06-30 45.14 21.42 4.43
2016-03-31 39.34 17.06 3.54
2015-12-31 39.09 20.27 3.42
2015-09-30 64.80 45.67 3.62
2015-06-30 40.61 20.99 3.69
2015-03-31 28.47 10.09 3.47
2014-12-31 30.27 10.74 3.44
2013-12-31 8.64 -11.24 2.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AC Immune has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if AC Immune has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if AC Immune improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AC Immune's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AC Immune has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

IMR Health

 How is AC Immune's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AC Immune's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AC Immune is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AC Immune's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of AC Immune's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 372.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AC Immune Company Filings, last reported 3 months ago.

DB:IMR Past Debt and Equity Data
Date (Data in CHF Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 177.62 0.52 186.46
2018-09-30 191.98 0.59 199.12
2018-06-30 95.39 0.55 102.66
2018-03-31 105.83 0.44 109.67
2017-12-31 116.84 0.49 124.38
2017-09-30 112.67 0.39 117.21
2017-06-30 120.89 0.39 124.18
2017-03-31 133.05 0.00 138.08
2016-12-31 142.38 0.00 152.21
2016-09-30 146.21 0.00 157.59
2016-06-30 90.54 0.00 82.38
2016-03-31 64.68 0.00 67.86
2015-12-31 71.04 0.00 76.52
2015-09-30 48.15 0.00 53.69
2015-06-30 29.00 0.00 19.36
2015-03-31 23.47 0.00 3.31
2014-12-31 23.47 0.00 3.31
2013-12-31 3.93 0.00 11.25
  • AC Immune's level of debt (0.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 0.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • AC Immune has sufficient cash runway for more than 3 years based on current free cash flow.
  • AC Immune has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 97.8% each year.
X
Financial health checks
We assess AC Immune's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AC Immune has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

IMR Dividends

 What is AC Immune's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AC Immune dividends. Estimated to be 0% next year.
If you bought €2,000 of AC Immune shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AC Immune's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AC Immune's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:IMR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:IMR Future Dividends Estimate Data
Date (Data in CHF) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AC Immune has not reported any payouts.
  • Unable to verify if AC Immune's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AC Immune's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AC Immune has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of AC Immune's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess AC Immune's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AC Immune afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AC Immune has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

IMR Management

 What is the CEO of AC Immune's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andrea Pfeifer
AGE 60
CEO Bio

Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPartners AG and is its Partner. She serves as an Advisor at the Nestlé Venture Capital Fund, which she co-founded. She has 25 years of senior management experience with broad research and development, business and international focus. She served as the Head of Nestlé’s Global Research and Development and managed a group of more than 600 people. She headed the Science and Technology Alliances group at Nestlé SA. While at Nestlé, she led the scientific development of the first Functional Food, LC1 and one of the first Cosmoceutical products in a joint venture with L'Oreal, Innéov Fermeté. Prof. Dr. Pfeifer directed the research department for life sciences, nutrition, food science and food safety and various other departments. She serves as Chairwoman at AB2 Bio Ltd., BioMedInvest AG I and BioMedInvest AG II. She serves as Chairwoman of the Biotechmedinvest AG Investment Fund, Basel. She has been a Member of the Supervisory Board at Symrise AG since May 18, 2011. She has been a Director of AC Immune SA since May 27, 2016. She served as a Member of Supervisory Board at Sygnis AG until October 17, 2012. She served as a Member of Supervisory Board at Sygnis Pharma AG from December 18, 2006 to October 17, 2012. She is a Member of the CEOi Initiative on Alzheimer’s Disease. She is also a Member of various Commissions and Boards, including the German Senate Commission on Food Safety, the Board of Directors of the Research Center for Environment and Health and the Swiss Association for Trade and Industry. She is an Honorary Professor at the Ecole Polytechnique Fédérale de Lausanne, Switzerland. She is a Lecturer at the IMD Business School in Lausanne and a Professor of Biotechnoloy at the University of Lausanne. She holds a professorship from the Federal Institute of Technology at Lausanne. She has published more than 200 papers and abstracts in leading scientific journals. In 2009, she was recognized as a Technology Pioneer by the WEF and Swiss Entrepreneur of the Year by Ernst&Young. Additional recognitions include the BioAlps prize 2013, the election as one of the top 10 women in biotech from Fierce Biotech and one of the 300 most influential personalities in Switzerland. She is a registered Pharmacist and Toxicologist and received her habilitation from the University of Lausanne, Switzerland. She is an international expert in biotechnology. She holds a Ph.D. in Toxicology and Cancer Research and a B.S. degree in Pharmacy from the University of Würzburg, Germany and continued with post-doctoral work in Molecular Carcinogenesis at the National Institutes of Health, Human Carcinogenesis Branch in Bethesda, USA.

CEO Compensation
  • Insufficient data for Andrea to compare compensation growth.
  • Insufficient data for Andrea to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the AC Immune management team in years:

3.8
Average Tenure
47
Average Age
  • The tenure for the AC Immune management team is about average.
Management Team

Andrea Pfeifer

TITLE
Co-Founder
AGE
60

Joerg Hornstein

TITLE
Chief Financial Officer
AGE
40
TENURE
2 yrs

Piergiorgio Donati

TITLE
Head of Technical Operations & Program Management
AGE
47
TENURE
0.2 yrs

Marie Kosco-Vilbois

TITLE
Chief Scientific Officer
AGE
60
TENURE
0.3 yrs

Jean-Fabien Monin

TITLE
Chief Administrative Officer
AGE
47
TENURE
3.8 yrs

Gautam Maitra

TITLE
Head of Regulatory & External Affairs and Senior Expert

Maria Pihlgren

TITLE
Head of Biology
TENURE
13.5 yrs

Wolfgang Fröstl

TITLE
Head of Chemistry
TENURE
13.3 yrs

Heiko Kroth

TITLE
Head of Chemistry

David Hickman

TITLE
Head of AD - SME
TENURE
9.3 yrs
Board of Directors Tenure

Average tenure and age of the AC Immune board of directors in years:

2.9
Average Tenure
64
Average Age
  • The average tenure for the AC Immune board of directors is less than 3 years, this suggests a new board.
Board of Directors

Martin Velasco

TITLE
Chairman
AGE
63

Andrea Pfeifer

TITLE
Co-Founder
AGE
60
TENURE
2.9 yrs

Jean-Marie Lehn

TITLE
Chairman of Scientific Advisory Board
AGE
79

Peter Bollmann

TITLE
Independent Non-Executive Director
AGE
65
TENURE
3.3 yrs

Doug Williams

TITLE
Director
AGE
60
TENURE
1 yrs

Fred Van Leuven

TITLE
Member of Scientific Advisory Board

I. Rosenberg

TITLE
Member of Scientific Advisory Board

Detlev Riesner

TITLE
Independent Non-Executive Director & Member of Scientific Advisory Board
AGE
76

Claude Nicolau

TITLE
Member of Scientific Advisory Board

M. Monsigny

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess AC Immune's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AC Immune has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

IMR News

Simply Wall St News

IMR Company Info

Description

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company’s lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase III clinical studies for the treatment of Alzheimer’s disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase I/IIa clinical study for AD; and ACI-35, an anti-Tau vaccine candidate against phosphorylated pathological tau and is in Phase Ib clinical testing in patients with mild to moderate AD, as well as RO7105705, an anti-Tau monoclonal antibody candidate, which is in Phase II clinical study for AD patients. In addition, the company has discovery and pre-clinical stage molecules targeting neurodegenerative diseases, as well as diagnostics targeting Tau, alpha-synuclein, and TDP-43 aggregates. It has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Piramal Imaging; Eli Lilly and Company; Essex Bio-Technology Limited; and WuXi Biologics, as well as Nestlé Institute of Health Sciences. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.

Details
Name: AC Immune SA
IMR
Exchange: DB
Founded: 2003
$283,560,732
67,562,333
Website: http://www.acimmune.com
Address: AC Immune SA
EPFL Innovation Park,
Building B,
Lausanne,
Vaud, 1015,
Switzerland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM ACIU Common Shares Nasdaq Global Market US USD 23. Sep 2016
DB IMR Common Shares Deutsche Boerse AG DE EUR 23. Sep 2016
Number of employees
Current staff
Staff numbers
98
AC Immune employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 22:08
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/03/22
Last earnings filing: 2019/03/21
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.